ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

パノビノスタット

Panobinostat

HCID 6918837
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
404950-80-7
標準SMILES
Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1
InChIKey
FPOHNWQLNRZRFC-ZHACJKMWSA-N
分子式
C21H23N3O2
平均分子量
349.4 g/mol
単同位体質量
349.17902698

概要

Panobinostat is a hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma. It has a role as an antineoplastic agent, an angiogenesis modulating agent and an EC 3.5.1.98 (histone deacetylase) inhibitor. It is a member of cinnamamides, a hydroxamic acid, a methylindole and a secondary amino compound. It is a conjugate base of a panobinostat(1+).

名称と識別子

優先名称
Panobinostat
IUPAC
(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
現地名
パノビノスタット
英語名
Panobinostat
分子式
C21H23N3O2
分子量
349.43

名称と別名

Panobinostat404950-80-7LBH-589FaridakLBH 589NVP-LBH5899647FM7Y3Z(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamideCHEBI:85990DTXSID401935062-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino)methyl)phenyl)-, (2E)-
名称をさらに表示
パノビノスタット(E)-N-ヒドロキシ-3-[4-[[[2-(2-メチル-1H-インドール-3-イル)エチル]アミノ]メチル]フェニル]アクリルアミド(E)-N-ヒドロキシ-3-[4-[[[2-(2-メチル-1H-インドール-3-イル)エチル]アミノ]メチル]フェニル]プロペンアミド(2E)-N-ヒドロキシ-3-[4-({[2-(2-メチル-1H-インドール-3-イル)エチル]アミノ}メチル)フェニル]プロパ-2-エンアミドpanobinostaCS-422Palcociclib2-AcrylamidePalmer than hePanobinostat D7Panobinostat, >=98%
2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino) methyl)phenyl)-, (2E)-2-Propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)-Panobinostatum(E)-N-hydroxy-3-(4-((2-(2-methyl-1H-indol-3-yl)ethylamino)methyl)phenyl)prop-2-enamide(2E)-N-HYDROXY-3-(4-(((2-(2-METHYL-1H-INDOL-3-YL)ETHYL)AMINO)METHYL)PHENYL)PROP-2-ENAMIDERefChem:56999NVP LBH589DTXCID10115997

物性

構造計算による物性補完中

XLogP
3
極性表面積
77.2 Ų
水素結合供与体数
4
水素結合受容体数
3
回転可能結合数
7
重原子数
26
形式電荷
0
複雑度
474

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
Human DrugsEMA approved medicines: Human medicine

物理化学的性質

融点
114 · 114-117C
比重(密度)
1.241 · 1.241±0.06 g/cm3(Predicted)
貯蔵温度
-20 °C · -20°C Freezer, Under Inert Atmosphere
溶解性
DMSO (最大 100mg/ml) またはエタノール (加熱により最大 5mg/ml) に可溶。
酸解離定数(Pka)
8.71 · 8.71±0.23(Predicted)
外見
個体
色
オフホワイト
安定性
-20 °C · -20°C の DMSO またはエタノール溶液で最大 1 か月間保存できます。
InChI
InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+
InChIKey
FPOHNWQLNRZRFC-ZHACJKMWSA-N
SMILES
C(NO)(=O)/C=C/C1=CC=C(CNCCC2C3=C(NC=2C)C=CC=C3)C=C1

化学的性質

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H301+H331 (97.2%): Toxic if swallowed or if inhaled [Danger Acute toxicity, oral; acute toxicity, inhalation]

P203, P260, P261, P264, P264+P265, P270, P271, P280, P301+P316, P302+P352, P304+P340, P305+P354+P338, P316, P317, P318, P319, P321, P330, P332+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 71 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 3 (98.6%)

毒性情報

Hepatotoxicity · 1 件

Most clinical trials of panobinostat have not reported rates of serum enzyme elevations during therapy and it is typically given in combination with other antineoplastic agents that can cause serum ALT and AST elevations. In the large controlled trial of panobinostat vs placebo in combination with bortezomib and dexamethasone, ALT elevations occurred in similar proportion of patients receiving panobinostat (31%) as placebo (38%) and values above 5 times the upper limit of normal were uncommon (1.8% and 1.3%). In addition, there have been no reports of clinically apparent liver injury with jaundice associated with panobinostat therapy. Thus, panobinostat appears to have little hepatotoxic potential and liver injury from panobinostat must be quite rare, if it occurs at all.

安全データ

wgk
WGK 3
hs_code
29339900
risk_code
22-36/37/38-20
safety_code
24/25

化学と産業

薬理情報

ATC Code · 3 件

L01XX42

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Mechanism of Action · 1 件

Panobinostat is a deacetylase (DAC) inhibitor. DACs, also known as histone DACs (HDAC), are responsible for regulating the acetylation of about 1750 proteins in the body; their functions are involved in many biological processes including DNA replication and repair, chromatin remodelling, transcription of genes, progression of the cell-cycle, protein degradation and cytoskeletal reorganization. In multiple myeloma, there is an overexpression of DAC proteins. Panobinostat inhibits class I (HDACs 1, 2, 3, 8), class II (HDACs 4, 5, 6, 7, 9, 10) and class IV (HDAC 11) proteins. Panobinostat's antitumor activity is believed to be attributed to epigenetic modulation of gene expression and inhibition of protein metabolism. Panobinostat also exhibits cytotoxic synergy with bortezomib, a proteasome inhibitor concurrently used in treatment of multiple myeloma.

Biological Half-Life30 hours
Metabolism/Metabolites · 1 件

Panobinostat was extensively metabolized to 77 metabolites. Unchanged panobinostat recovered in urine and feces was 2% and 3%, respectively. Primary metabolic pathways of panobinostat are reduction, hydrolysis, oxidation, and glucuronidation processes. CYP and non-CYP enzymes were found to play significant role in metabolism, CYP2D6 and CYP2C19 playing minor roles.

FDA Pharmacological Classification · 6 件

9647FM7Y3Z

histone deacetylase (HDAC) inhibitor

Established Pharmacologic Class [EPC] - Histone Deacetylase Inhibitor

Mechanisms of Action [MoA] - Histone Deacetylase Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 2D6 Inhibitors

Histone deacetylase (hdac) inhibitor is a Histone Deacetylase Inhibitor. The mechanism of action of histone deacetylase (hdac) inhibitor is as a Histone Deacetylase Inhibitor and Cytochrome P450 2D6 Inhibitor.

MeSH Pharmacological Classification

関連反応

7 件
反応記録を作成
HRID 43286 の反応式
HRID 43286生成物として
HRID 1669594 の反応式
HRID 1669594反応物として
HRID 1669595 の反応式
HRID 1669595反応物として
HRID 1669596 の反応式
HRID 1669596反応物として
HRID 1669597 の反応式
HRID 1669597反応物として
HRID 1669861 の反応式
HRID 1669861反応物として
HRID 1669862 の反応式
HRID 1669862反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
404950-80-7
PubChem CID
6918837
DTXSID
DTXSID40193506
ChEMBL
CHEMBL483254
ChEBI
CHEBI:85990
UNII
9647FM7Y3Z
EC Number
803-814-1
Nikkaji
J2.554.199E、J3.451.397J

化学的特性Yellow Solid

Hazard Classifications
Acute Tox. 3 InhalationAcute Tox. 3 OralEye Dam. 1Repr. 1BSkin Irrit. 2STOT RE 2 Inhalation
ストレージクラス
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
· 2 件

Substances that inhibit or prevent the proliferation of NEOPLASMS.

Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.

Absorption, Distribution and ExcretionAfter a 20 mg dose, panobinostat was quickly absorbed with a time to maximum absorption of 2 hours.
応用分野 · 2 件

説明Panobinostat is a potent inhibitor of all histone deacetylases (HDACs), with Ki values ranging from 0.6 to 31 nM for HDAC1-11. Through this action, it leads to acetylation of a range of cellular proteins, resulting in cell cycle arrest and apoptosis in cancer cells. It has potential applications in several different forms of cancer as well as in spinal muscular atrophy and HIV therapy.

使用The novel labelled histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells.

上流・下流製品情報

上流原料

パノビノスタットカルボン酸メチルエステル塩酸塩塩酸ヒドロキシルアミン水酸化ナトリウム
補足説明 · 1 件

定義ChEBI: A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its la tate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.